Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Tefferi

Showing results (181-190 of 346) with videos related to

Pageof 35
Sort By:
Blood|July 1, 1989
Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinomaA Tefferi, B A Owen, W L Nichols, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indicationsA Tefferi, M N Silverstein, R M Petitt, et al.
Leukemia|June 4, 2014
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classificationT Barbui, J Thiele, H M Kvasnicka, et al.
Acta Dermato-Venereologica|January 1, 1989
Transient acantholytic dermatosis associated with lymphomatous angioimmunoblastic lymphadenopathyB D Zelickson, A Tefferi, M A Gertz, et al.
Leukemia|January 31, 2014
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblastsM M Patnaik, A Belachew, C Finke, et al.
Mayo Clinic Proceedings|February 1, 1992
Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemiaD L Graham, A Tefferi, L Letendre, et al.
American Journal of Clinical Oncology|October 1, 1995
Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemiaL Letendre, P Noel, A Tefferi, et al.
Leukemia|March 21, 2008
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patientsT L Lasho, A Tefferi, J D Hood, et al.
Leukemia|June 19, 2012
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcomeA Pardanani, A D'Souza, R A Knudson, et al.
Leukemia|January 16, 2013
Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype studyA Pardanani, C Finke, R A Abdelrahman, et al.
Pageof 35

Showing results (181-190 of 346) with videos related to

Sort By:
Pageof 35
Blood|July 1, 1989
Isolation of a heparin-like anticoagulant from the plasma of a patient with metastatic bladder carcinomaA Tefferi, B A Owen, W L Nichols, et al.
Seminars in Thrombosis and Hemostasis|January 1, 1997
Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of actin, efficacy, toxicity, current indicationsA Tefferi, M N Silverstein, R M Petitt, et al.
Leukemia|June 4, 2014
Essential thrombocythemia with high hemoglobin levels according to the revised WHO classificationT Barbui, J Thiele, H M Kvasnicka, et al.
Acta Dermato-Venereologica|January 1, 1989
Transient acantholytic dermatosis associated with lymphomatous angioimmunoblastic lymphadenopathyB D Zelickson, A Tefferi, M A Gertz, et al.
Leukemia|January 31, 2014
CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblastsM M Patnaik, A Belachew, C Finke, et al.
Mayo Clinic Proceedings|February 1, 1992
Cytogenetic and molecular detection of residual leukemic cells after allogeneic bone marrow transplantation in chronic granulocytic leukemiaD L Graham, A Tefferi, L Letendre, et al.
American Journal of Clinical Oncology|October 1, 1995
Continuous infusion etoposide/carboplatin for treatment of refractory acute leukemiaL Letendre, P Noel, A Tefferi, et al.
Leukemia|March 21, 2008
TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patientsT L Lasho, A Tefferi, J D Hood, et al.
Leukemia|June 19, 2012
Long-term follow-up of FIP1L1-PDGFRA-mutated patients with eosinophilia: survival and clinical outcomeA Pardanani, A D'Souza, R A Knudson, et al.
Leukemia|January 16, 2013
Increased circulating IL-2Rα (CD25) predicts poor outcome in both indolent and aggressive forms of mastocytosis: a comprehensive cytokine-phenotype studyA Pardanani, C Finke, R A Abdelrahman, et al.
Pageof 35